In the GIST group, no patients had a confirmed response and recruitment was discontinued at the first step.
Twenty-one patients had a confirmed response of partial response or better (60.0%; 95% CI 42.1 76.1), with two (6%) patients achieving a stringent complete response, and an additional three (9%) achieving a complete response, 14 (40%) achieving a very good partial response, and two (6%) achieving a partial response (Figs. 2a, 3a).
For patients who had received prior proteasome inhibitor treatment for myeloma (n=19), 11% had a confirmed response of VGPR or better, 21% had a confirmed response of PR, 11% had a confirmed response of MR and 32% had SD.
Among patients whose disease was considered relapsed and refractory to prior proteasome inhibitor treatment (n=13), 15% had a confirmed response of PR, 15% had a confirmed response of MR and 39% had SD.
NGR-hTNF induced a confirmed response rate of 7%, a DCR of 30%, and a median survival of 8.9 months.
The observed clinical activity with a confirmed response rate of 75% is promising and further evaluated in the ongoing CELIM2.
For patients who had received prior lenalidomide treatment for myeloma, 15% had a confirmed response of VGPR or better, and an additional 15% had a confirmed response of PR, with 31% having SD; in patients whose disease was considered relapsed and refractory to prior lenalidomide treatment, 10% had a confirmed response of PR and 40% had SD.
Among patients who had not received lenalidomide treatment before enrolling in this study (lenalidomide naive), 24% had a confirmed response of VGPR or better, 35% had a confirmed response of PR, 18% had a confirmed response of MR and 24% had SD.
In patients who had not received proteasome inhibitor treatment before enrolling in this study (proteasome inhibitor naive; n=10), 30% had a confirmed response of VGPR or better, 40% had a confirmed response of PR, 10% had a confirmed response of MR and 20% had SD.
And 50% of the patients who had a 50% reduction in CA19-9 also had a confirmed response by RECIST, compared with 15% in those who did not.
For example, we may be interested in relapse in the time period between a confirmed response and the first relapse of cancer.
